drugset / Trial / NCT05692154

A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

NCT05692154

Phase 3 Completed 95 enrolled Opella Healthcare Group SAS
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of preventing Allergic Rhinitis (AR) symptoms. The total study duration per participant is expected at least 4 months, depending on the timing of the screening visit. 5 visits are planned, screening, confirmation inclusion challenge, randomization visit, challenge and end of study visit.

Timeline

Start
2023-01-23
Primary completion
2023-03-14
Completion
2023-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexofenadine Unknown 180 mg Oral